Modulation of autophagy with hydroxychloroquine in patients with advanced non-small cell lung cancer (NSCLC): A phase Ib study.

被引：9
|
作者：
Malhotra, Jyoti
Jabbour, Salma
Orlick, Michelle
Riedlinger, Gregory
Joshi, Sonali
Guo, Jessie Yanxiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21138
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Rodon, Jordi
    Jacobs, Charlotte D.
    Chu, Quincy
    Rowinsky, Eric K.
    Lopez-Anaya, Arturo
    Takimoto, Chris H.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 825 - 834
  • [32] Phase II study of Gemcitabine, ifosfamide and cisplatin (GIP) in patients with advanced non-small cell lung cancer (NSCLC)
    De las Penas, R
    Busquier, I
    Munarriz, J
    Lopez, A
    Llorente, R
    Alberola, V
    Frau, A
    ANNALS OF ONCOLOGY, 1998, 9 : 88 - 88
  • [33] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [34] Phase II study of topotecan and bevacizumab in advanced refractory non-small cell lung cancer (NSCLC).
    Powell, S. F.
    Beitinjaneh, A.
    Bliss, R. L.
    Kratzke, R. A.
    Leach, J. W.
    Dudek, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] ACTIVITY OF PATUPILONE IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
    Zatloukal, P.
    Mellemgaard, A.
    Sanchez, J. M.
    Perry, M. C.
    Hamm, J. T.
    Van Meerbeeck, J.
    DeLeo, J. J.
    Gao, B.
    Johri, A. R.
    Felip, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 109 - 109
  • [36] A phase II and pharmacogenomic study of Irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC).
    Pillot, GA
    Hennenfent, K
    Read, W
    Marsh, S
    McLeod, HL
    Gao, F
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 648S - 648S
  • [37] Patient attitude and survival in advanced non-small cell lung cancer (NSCLC): Results of a prospective observational study.
    Altug, S.
    Wang, L.
    Chu, D.
    Park, K.
    Hsu, H.
    Cok, G.
    Roubec, J.
    Patil, S.
    Damyanov, D.
    Reece, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 401S - 401S
  • [38] Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203.
    Edelman, M. J.
    Watson, D. M.
    Wang, X.
    Kratzke, R. A.
    Mauer, A. M.
    Green, M. R.
    Vokes, E. E.
    Graziano, S. L.
    Masters, G. A.
    Bedor, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 370S - 370S
  • [39] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
    Borghaei, Hossein
    Besse, Benjamin
    Bardia, Aditya
    Mazieres, Julien
    Popat, Sanjay
    Augustine, Bincy
    D'amelio, Anthony Michael
    Barrios, Daniel
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Phase II study of dasatinib in non-small cell lung cancer (NSCLC)
    Johnson, F. M.
    Tang, X.
    Tran, H.
    Saigal, B.
    Erasmus, J.
    Kurie, J.
    Hwang, L.
    Oh, Y.
    Lippman, S.
    Stewart, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345